<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01140828</url>
  </required_header>
  <id_info>
    <org_study_id>RAN Study</org_study_id>
    <nct_id>NCT01140828</nct_id>
  </id_info>
  <brief_title>A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal Injury</brief_title>
  <official_title>A Double-blind Randomized Placebo Controlled Trial of Rabeprazole for Prevention of NSAID-associated Dyspepsia and Gastroduodenal Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether rabeprazole is superior to placebo in&#xD;
      preventing dyspepsia and gastroduodenal injury in subjects with osteoarthritis (OA) and/or&#xD;
      rheumatoid arthritis (RA) and/or bone pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non steroidal anti-inflammatory drugs (NSAIDs) are well known to increase the risk of&#xD;
      gastroduodenal (GD) ulcer and its complications. Up to 40% of average-risk NSAID users suffer&#xD;
      from dyspepsia without endoscopic evidence of gastroduodenal injury. It results a significant&#xD;
      loss of productivity and impairment of Quality of Life (QoL). Proton pump inhibitors (PPIs)&#xD;
      have been shown to be effective in preventing and reducing NSAID-induced GD injury. PPIs are&#xD;
      believed to have a class effect but Rabeprazole, the least expensive PPI, is grossly&#xD;
      under-utilized in this area .&#xD;
&#xD;
      Current Hospital Authority (HA) guidelines, however, only endorse the use of PPI in patients&#xD;
      at high risk of ulcer bleeding. Since NSAID-induced dyspepsia is not an indication for PPI&#xD;
      according to HA guidelines, those patients do not receive PPI for treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-week cumulative incidence of gastric/duodenal ulcer, &gt;10 erosions or severe dyspepsia</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Arthritis, Rheumatoid</condition>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Rabeprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rabeprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rabeprazole Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Rabeprazole Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole</intervention_name>
    <description>Rabeprazole 20mg once daily</description>
    <arm_group_label>Rabeprazole</arm_group_label>
    <other_name>Pariet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole Placebo</intervention_name>
    <description>one tab once daily</description>
    <arm_group_label>Rabeprazole Placebo</arm_group_label>
    <other_name>Pariet Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatient or inpatient subjects with a clinical diagnosis of OA or RA or any bone&#xD;
             pain&#xD;
&#xD;
          -  Subjects expected to require regular anti-inflammatory therapy for arthritis symptom&#xD;
             management&#xD;
&#xD;
          -  Subjects should have no history of peptic ulcer complications&#xD;
&#xD;
          -  Screening tests are negative for H pylori&#xD;
&#xD;
          -  Subjects who test positive can be re-screened after eradication of H. pylori&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of gastrointestinal (GI) hemorrhage&#xD;
&#xD;
          -  History of gastric or duodenal surgery&#xD;
&#xD;
          -  Presence of erosive esophagitis, gastric-outlet obstruction&#xD;
&#xD;
          -  Likelihood of requiring treatment during the study with drugs not permitted by the&#xD;
             protocol&#xD;
&#xD;
          -  Impaired hepatic function (SGPT (ALT) or serum glutamate oxaloacetate transaminase&#xD;
             (SGOT) (AST) &gt; 2 x upper limit of normal) or renal function (serum creatinine &gt; 200&#xD;
             umol/l)&#xD;
&#xD;
          -  Any other condition or baseline finding which, in the investigator's judgment, might&#xD;
             increase risk to the subject or decrease the chance of obtaining satisfactory data to&#xD;
             achieve study objectives&#xD;
&#xD;
          -  Anemia with Hb &lt; 10 g/dL&#xD;
&#xD;
          -  Suspected or clinical diagnosis of inflammatory bowel disease&#xD;
&#xD;
          -  Congestive heart failure (NYHA class III- IV)&#xD;
&#xD;
          -  Subjects considered to have a requirement for continued use of:&#xD;
&#xD;
               -  Corticosteroids (dose equivalent of prednisolone/ prednisone &gt;10mg daily stable&#xD;
                  dose)&#xD;
&#xD;
               -  disease-modifying antirheumatic drug (DMARDs) (unless stable dose for ≥ 12 weeks)&#xD;
&#xD;
               -  Iron replacement therapy (a dose &gt; 15mg elemental iron/day)&#xD;
&#xD;
               -  Iron replacement therapy (a dose &gt; 15mg elemental iron/day) or supplements for&#xD;
                  deficiency prevention (a dose ≤ 15mg elemental iron/day) due to anemia or any&#xD;
                  other reason&#xD;
&#xD;
               -  Double anti-platelet therapy (e.g. aspirin + Plavix)&#xD;
&#xD;
               -  Anti-coagulants&#xD;
&#xD;
               -  Anti-ulcer medications, e.g. sucralfate, H2 receptor antagonists (H2RAs),&#xD;
                  misoprostol, PPIs other than study medications&#xD;
&#xD;
               -  Sucralfate, misoprostol or regular H2 receptor antagonists (H2RAs) (&gt; 3&#xD;
                  days/week)&#xD;
&#xD;
               -  COX-2 inhibitors&#xD;
&#xD;
               -  anti-ulcer medications or COX-2 selective inhibitor at screening allowed if&#xD;
                  treatments discontinued at this time&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis K Chan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>June 9, 2010</study_first_submitted>
  <study_first_submitted_qc>June 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2010</study_first_posted>
  <last_update_submitted>August 21, 2015</last_update_submitted>
  <last_update_submitted_qc>August 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Francis KL Chan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Arthritis</keyword>
  <keyword>Bone pain</keyword>
  <keyword>dyspepsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

